AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation
November 23, 2020 08:30 ET
|
ARCA biopharma, Inc.
Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or notAB201 is the only novel compound being developed for COVID Associated...
ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update
November 02, 2020 08:30 ET
|
ARCA biopharma, Inc.
Initiation of Phase 2b clinical trial evaluating AB201 as a potential treatment for COVID19 anticipated in fourth quarterTopline data from trial anticipated Q2 2021 WESTMINSTER, Colo., Nov. 02,...
RedHill Biopharma Announces Partnerships to Expand Manufacturing for COVID-19 Therapeutic Candidate Opaganib
October 13, 2020 10:30 ET
|
RedHill Biopharma Ltd.
Collaborations with European and Canadian suppliers for large-scale ramp-up of opaganib manufacturing further strengthens manufacturing capabilities and capacity, in preparation for potential...
RedHill Biopharma’s Opaganib COVID-19 Study Passes Second Independent Committee Review
October 07, 2020 10:00 ET
|
RedHill Biopharma Ltd.
Second pre-scheduled independent Safety Monitoring Committee (SMC) review unanimously recommends continuation without change of the U.S. Phase 2 study with opaganib in COVID-19 --The U.S. Phase 2...
Renibus Therapeutics’ COVID-19 Treatment, RBT-9, Shows Antiviral Activity Against SARS-CoV-2 In Vitro
October 07, 2020 09:00 ET
|
Rénibus Therapeutics Inc.
DALLAS, Texas, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that its investigational treatment for COVID-19, RBT-9, has...
ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19
October 07, 2020 08:30 ET
|
ARCA biopharma, Inc.
Initiation of Phase 2b clinical trial anticipated in Q4 2020Trial to enroll approximately 100 patients hospitalized with COVID-19Topline data anticipated Q2 2021 WESTMINSTER, Colo., Oct. 07, 2020 ...
C-Bond Systems Enters into $1 Million Exclusive Distribution Agreement for its MB-10 and FN Nano Products with Prominent Distributor in India
August 31, 2020 08:45 ET
|
C-Bond Systems
HOUSTON, Aug. 31, 2020 (GLOBE NEWSWIRE) -- C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a nanotechnology solutions company, announced today that it has entered into a $1 million exclusive...
Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update
August 05, 2020 16:15 ET
|
ARCA biopharma, Inc.
AB201 being developed as a potential treatment for COVID-19 and other RNA virus associated diseasesARCA anticipates filing an IND for AB201 in Q3 2020 and initiating Phase 2 clinical testing in Q4...
C-Bond Systems Reports Record Monthly Revenue of $128,000 in July
August 03, 2020 08:31 ET
|
C-Bond Systems
HOUSTON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a nanotechnology solutions company, announced today that it has reported record monthly revenue of...
Avid Bioservices and Argonaut Manufacturing Services Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Process Development, Drug Substance Manufacturing and Drug Product Parenteral Manufacturing
July 28, 2020 08:05 ET
|
Avid Bioservices, Inc; Argonaut Manufacturing Services
TUSTIN, Calif. and CARLSBAD, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing...